A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

April 21, 2027

Study Completion Date

April 21, 2029

Conditions

Metastatic TumorAdvanced Solid TumorRenal Cell CarcinomaOvarian CancerCervix CancerHead and Neck Squamous Cell CarcinomaNasopharyngeal Carcinoma

Interventions

DRUG

CHT101

After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.

All Listed Sponsors

lead

Zhejiang University

OTHER

NCT06383507 - A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter